AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8540598 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 35
Study 8540598 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 35
Study 8540598 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 35
Study 2050827 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (750 mg IV) with probenecid (2 g orally)
Number of subjects: 6
Study 2050827 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (750 mg IV) without probenecid
Number of subjects: 6
Study 31781762 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir (LET) prophylaxis
Number of subjects: 79
Study 31781762 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir preemptive therapy
Number of subjects: 79
Study 30962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 100 mg once a day (qd)
Number of subjects: 0
Study 30962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg and above
Number of subjects: 0
Study 30962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan up to 10 µg/mL
Number of subjects: 0
Study 30962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan (single and multiple doses)
Number of subjects: 0
Study 30962677 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan (100 mg qd)
Number of subjects: 0
Study 28104204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 110
Study 28104204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 110
Study 28104204 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 110
Study 25624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.3mg/kg)
Number of subjects: 45
Study 25624076 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1mg/kg)
Number of subjects: 45
Study 23266359 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg fesoterodine tablet formulation (test)
Number of subjects: 12
Study 23266359 — intervention group
Group type: COMPARATOR
Intervention: 8mg fesoterodine tablet formulation (reference)
Number of subjects: 12
Study 22145774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated pea flour (FPF)
Number of subjects: 23
Study 22145774 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole yellow pea flour (WPF)
Number of subjects: 23
Study 22145774 — intervention group
Group type: COMPARATOR
Intervention: White wheat flour (WF)
Number of subjects: 23
Study 19699846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 569
Study 19699846 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 569
Study 17605561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 2481
Study 17605561 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 2481
Study 15472806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (100 mg on day 1, followed by 50 mg per day)
Number of subjects: 601
Study 15472806 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (200 mg on day 1, followed by 100 mg per day)
Number of subjects: 601
Study 15472806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 601
Study 15472806 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 601
Study 11520994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation
Number of subjects: 100
Study 11520994 — intervention group
Group type: COMPARATOR
Intervention: Nutritional status assessment
Number of subjects: 100
Study 11520994 — intervention group
Group type: COMPARATOR
Intervention: Feeding skill score assessment
Number of subjects: 100
Study 11520994 — intervention group
Group type: COMPARATOR
Intervention: Parental awareness assessment
Number of subjects: 100
Study 11520994 — intervention group
Group type: COMPARATOR
Intervention: Comparison of feeding problems in cases with and without seizures
Number of subjects: 100
Study 9782437 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 45
Study 9782437 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron hydrochloride
Number of subjects: 45
Study 7838909 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 0
Study 7838909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3078909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiorinal with Codeine
Number of subjects: 154
Study 3078909 — intervention group
Group type: COMPARATOR
Intervention: Fiorinal alone
Number of subjects: 154
Study 3078909 — intervention group
Group type: COMPARATOR
Intervention: Codeine alone
Number of subjects: 154
Study 3078909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 30297162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine deprivation
Number of subjects: 22
Study 30297162 — intervention group
Group type: COMPARATOR
Intervention: Participants without psychiatric conditions
Number of subjects: 22
Study 28817424 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE simulator training for 4 hours
Number of subjects: 44
Study 28817424 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based training only (Control)
Number of subjects: 44
Study 28817424 — intervention group
Group type: COMPARATOR
Intervention: Expert group
Number of subjects: 44
Study 28817424 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE simulator training
Number of subjects: 44
Study 28817424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 25775072 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60
Study 25775072 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 60
Study 23088300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active paraplegic group
Number of subjects: 22
Study 23088300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary paraplegic group
Number of subjects: 22
Study 23088300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 21082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA
Number of subjects: 73
Study 21082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA‐BMA
Number of subjects: 73
Study 21082870 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 73
Study 19074619 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (focusing on the disk)
Number of subjects: 14
Study 19074619 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus (focusing on reducing movements of their feet)
Number of subjects: 14
Study 19074619 — intervention group
Group type: COMPARATOR
Intervention: Control (no attentional focus instructions)
Number of subjects: 14
Study 17132410 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding (GB)
Number of subjects: 80
Study 17132410 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic isolated sleeve gastrectomy (SG)
Number of subjects: 80
Study 15310562 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training program
Number of subjects: 116
Study 15310562 — intervention group
Group type: COMPARATOR
Intervention: Normal training routine (Control)
Number of subjects: 116
Study 11748787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 206
Study 11748787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 206
Study 11748787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 206
Study 11748787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 11748787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 206
Study 9265425 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated catheters with minocycline and rifampin
Number of subjects: 281
Study 9265425 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheters
Number of subjects: 281
Study 8489556 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A (doses > or = 0.5 mg)
Number of subjects: 0
Study 8489556 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A (multiple doses)
Number of subjects: 0
Study 8489556 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A (single oral dose)
Number of subjects: 0
Study 8489556 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A
Number of subjects: 0
Study 3435099 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg
Number of subjects: 44
Study 3435099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29220524 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 176
Study 29220524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 176
Study 29220524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 29220524 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and Bupropion
Number of subjects: 176
Study 28074483 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised estimating equations with independence working correlation structure
Number of subjects: 0
Study 28074483 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised estimating equations with exchangeable working correlation structure
Number of subjects: 0
Study 28074483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomisation
Number of subjects: 0
Study 28074483 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual randomisation
Number of subjects: 0
Study 28074483 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomisation to opposite treatment groups
Number of subjects: 0
Study 26079259 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemstone Spectral Imaging (GSI) with 300mgI/kg contrast material (group A)
Number of subjects: 47
Study 26079259 — intervention group
Group type: COMPARATOR
Intervention: Conventional 120 kVp tube voltage with 450mgI/kg contrast material (group B)
Number of subjects: 47
Study 23561927 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient priming
Number of subjects: 208
Study 23561927 — intervention group
Group type: COMPARATOR
Intervention: Inpatient priming
Number of subjects: 208
Study 21181960 — intervention group
Group type: EXPERIMENTAL
Intervention: Various definitions of mixed urinary incontinence (MUI) based on baseline incontinence measures (MESA questionnaire, Urogenital Distress Inventory, 7-day urinary diary)
Number of subjects: 307
Study 21181960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold symptom-based definitions of MUI
Number of subjects: 307
Study 21181960 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of urinary incontinence severity
Number of subjects: 307
Study 19808853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with weight loss (EWL)
Number of subjects: 34
Study 19808853 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with weight loss (CR)
Number of subjects: 34
Study 19808853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training without weight loss (EX)
Number of subjects: 34
Study 19808853 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study 17205304 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking solution (formulation 1)
Number of subjects: 10
Study 17205304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation 2B
Number of subjects: 10
Study 17205304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation 2C
Number of subjects: 10
Study 15229119 — intervention group
Group type: COMPARATOR
Intervention: Dietary antioxidant index (quintiles)
Number of subjects: 27111
Study 12270860 — intervention group
Group type: COMPARATOR
Intervention: Tissue angiogenesis in patients without ischemic complications (score: 5.69+/‐0.6)
Number of subjects: 69
Study 12270860 — intervention group
Group type: COMPARATOR
Intervention: Tissue angiogenesis in patients with strong acute phase response (score: 5.31+/‐0.6)
Number of subjects: 69
Study 12270860 — intervention group
Group type: COMPARATOR
Intervention: Serum angiogenic activity in patients without ischemic events (optical density x1000, 270+/‐15)
Number of subjects: 69
Study 12270860 — intervention group
Group type: COMPARATOR
Intervention: Serum angiogenic activity in patients without ischemic events (107+/‐5 relative units)
Number of subjects: 69
Study 12270860 — intervention group
Group type: COMPARATOR
Intervention: In vivo full angiogenic activity tested in the chick chorioallantoic membrane
Number of subjects: 69
Study 9832300 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg single dose
Number of subjects: 24
Study 8607318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 120
Study 8607318 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5.0 mg/kg
Number of subjects: 120
Study 8607318 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 6.0 mg/kg
Number of subjects: 120
Study 2693440 — intervention group
Group type: EXPERIMENTAL
Intervention: Gugulipid (500 mg tds for 12 weeks after 8 weeks of diet and placebo)
Number of subjects: 205
Study 2693440 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 205
Study 324487 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 20
Study 324487 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 20
Study 324487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29630416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention for 8 weeks
Number of subjects: 0
Study 28260223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5‐mg tablets and pregabalin 75‐mg capsules bid (Group A)
Number of subjects: 500
Study 28260223 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5‐mg tablets (Group B)
Number of subjects: 500
Study 28260223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75‐mg capsules bid (Group C)
Number of subjects: 500
Study 28260223 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 500
Study 26282525 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Eating (GE) Project intervention
Number of subjects: 608
Study 26282525 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treatment)
Number of subjects: 608
Study 22626910 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 275
Study 22626910 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious patients
Number of subjects: 275
Study 22626910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for depressed patients
Number of subjects: 275
Study 22626910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for anxious patients
Number of subjects: 275
Study 22626910 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic factors
Number of subjects: 275
Study 22626910 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 275
Study 21204963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cardiovascular risk factor intervention
Number of subjects: 81
Study 21204963 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes clinic attendance
Number of subjects: 81
Study 17509580 — intervention group
Group type: EXPERIMENTAL
Intervention: Estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen)
Number of subjects: 18
Study 17509580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16429427 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast taken in the morning for 2 weeks
Number of subjects: 24
Study 16429427 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast taken in the evening for 2 weeks
Number of subjects: 24
Study 12768153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex/SP Gel (1-3 mL)
Number of subjects: 34
Study 12768153 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 34
Study 10681072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (50-100 mg)
Number of subjects: 324
Study 10681072 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg)
Number of subjects: 324
Study 9501335 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (0.15-0.17 mg/m3)
Number of subjects: 60
Study 9501335 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (0.03-0.08 mg/m3)
Number of subjects: 60
Study 9501335 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (0.02-0.03 mg/m3)
Number of subjects: 60
Study 9501335 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed)
Number of subjects: 60
Study 1439620 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac and 200 micrograms misoprostol)
Number of subjects: 455
Study 1439620 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac (control)
Number of subjects: 455
Study 1439620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Arthrotec and diclofenac)
Number of subjects: 455
Study 3093827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 170
Study 3093827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 30024627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A soft capsules for 7 days
Number of subjects: 60
Study 30024627 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti‐inflammatory therapy and aerosol inhalation
Number of subjects: 60
Study 26162646 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (15.0 g/day, 5 g three times a day)
Number of subjects: 88
Study 26162646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24338990 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy
Number of subjects: 684
Study 24338990 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation radiotherapy
Number of subjects: 684
Study 23323673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g kg(‐1) body mass sodium bicarbonate (NaHCO3)
Number of subjects: 10
Study 23323673 — intervention group
Group type: COMPARATOR
Intervention: 0.1 g kg(‐1) body mass sodium chloride (placebo)
Number of subjects: 10
Study 21632213 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 72
Study 21632213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 17468868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 0.75 mg
Number of subjects: 0
Study 17468868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 1.5 mg
Number of subjects: 0
Study 17468868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg
Number of subjects: 0
Study 17468868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 3.0 mg
Number of subjects: 0
Study 17468868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16996845 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-rate pacing (80 pulses per minute)
Number of subjects: 49
Study 16996845 — intervention group
Group type: COMPARATOR
Intervention: Lower-rate pacing (60 pulses per minute)
Number of subjects: 49
Study 14535871 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐methacetin breath test (75 mg per os)
Number of subjects: 28
Study 14535871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative 13C‐methacetin breath test
Number of subjects: 28
Study 11085191 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/kg/d of ZnSO4)
Number of subjects: 18
Study 11085191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8930174 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 21
Study 8930174 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 21
Study 8930174 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Quinapril
Number of subjects: 21
Study 8930174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1403755 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tunnel scleral pocket incision
Number of subjects: 129
Study 1403755 — intervention group
Group type: COMPARATOR
Intervention: Superficial scleral pocket incision
Number of subjects: 129
Study 3325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg, twice daily for a mean duration of 8.77 days
Number of subjects: 667
Study 3325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg, twice daily for a mean duration of 8.77 days
Number of subjects: 667
Study 3325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 800 mg, twice daily for a mean duration of 8.77 days
Number of subjects: 667
Study 3325260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (all dosages combined)
Number of subjects: 667
Study 29444690 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg NBMI
Number of subjects: 36
Study 29444690 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg NBMI
Number of subjects: 36
Study 29444690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27491778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 20
Study 27491778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24445732 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly follow-up with the SFP program (group A)
Number of subjects: 102
Study 24445732 — intervention group
Group type: COMPARATOR
Intervention: Referral to primary care physician with a single SFP program visit at 24 months (group B)
Number of subjects: 102
Study 22220935 — intervention group
Group type: EXPERIMENTAL
Intervention: Active MIRE
Number of subjects: 30
Study 22220935 — intervention group
Group type: COMPARATOR
Intervention: Sham MIRE (placebo group)
Number of subjects: 30